RenovoRx Past Earnings Performance
Past criteria checks 0/6
RenovoRx's earnings have been declining at an average annual rate of -12.9%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been growing at an average rate of 94.1% per year.
Key information
-12.93%
Earnings growth rate
33.34%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 94.13% |
| Return on equity | -108.91% |
| Net Margin | -823.98% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
RNXT: Phase III Pancreatic Cancer Data And New Patent Portfolio Will Drive Upside
Analysts have updated their price target on RenovoRx stock from $5.56 to $7.03, citing revisions to fair value assumptions, discount rate, expected revenue growth, profit margin outlook, and future P/E estimates. What's in the News for RenovoRx RenovoRx reported publication of a peer reviewed case study from Moffitt Cancer Center in Radiology Case Reports, describing use of its TAMP procedure and RenovoCath device to deliver intra arterial gemcitabine in locally advanced pancreatic cancer, with PET CT showing a 52% reduction in tumor metabolic activity at 4 month follow up.Here's Why We're Watching RenovoRx's (NASDAQ:RNXT) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...RenovoRx (NASDAQ:RNXT) Is Revolutionizing Cancer Treatment
RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment. Using its Trans-Arterial Micro-Perfusion (TAMP™) platform, the company aims to solve a major issue in cancer care: how to get strong doses of chemo directly to the tumor while avoiding harmful side effects throughout the body.Revolutionizing Cancer Treatment
A small incision is made in the leg to insert the RenovoCath® system.RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount
Summary RenovoRx's innovative RenovoCath and TAMP platform show promising clinical data, extending pancreatic cancer survival rate 5 months and improving quality of life. The company’s market cap of $70M is undervalued compared to an intrinsic value of $243M, driven by early commercial traction and strategic partnerships. Leadership and advisory board bring extensive experience, enhancing RenovoRx's potential for successful commercialization and market expansion. Positive clinical data, physician demand, and a new reimbursement code accelerated RenovoCath sales by an estimated 2 years. Read the full article on Seeking AlphaWe Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is RenovoRx (NASDAQ:RNXT) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Companies Like RenovoRx (NASDAQ:RNXT) Could Be Quite Risky
Just because a business does not make any money, does not mean that the stock will go down. For example, although...RenovoRx reports Q2 results
RenovoRx press release (NASDAQ:RNXT): Q2 Net Loss of $2.6M As of June 30, 2022, the company had cash and cash equivalents and short-term marketable securities of $10.8M.Is RenovoRx (NASDAQ:RNXT) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...RenovoRx names new finance CFO
RenovoRx (NASDAQ:RNXT) appoints James Ahlers as CFO, effective July 15, 2022, and the addition of Ronald B. Kocak as VP and Controller. Mr. Ahlers replaces Christopher J. Lehman, who joined in connection with its IPO and is leaving to pursue a new business opportunity. Mr. Ahlers served as CFO of Intarcia Therapeutics and has held senior finance roles with Titan Pharmaceuticals and Ansan Pharmaceuticals.RenovoRx (NASDAQ:RNXT) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We Think RenovoRx (NASDAQ:RNXT) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...Revenue & Expenses Breakdown
How RenovoRx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 1 | -12 | 8 | 5 |
| 31 Dec 25 | 1 | -11 | 7 | 6 |
| 30 Sep 25 | 1 | -11 | 6 | 6 |
| 30 Jun 25 | 1 | -11 | 5 | 6 |
| 31 Mar 25 | 0 | -10 | 5 | 6 |
| 31 Dec 24 | 0 | -9 | 5 | 6 |
| 30 Sep 24 | 0 | -9 | 5 | 5 |
| 30 Jun 24 | 0 | -8 | 5 | 5 |
| 31 Mar 24 | 0 | -8 | 5 | 6 |
| 31 Dec 23 | 0 | -10 | 6 | 6 |
| 30 Sep 23 | 0 | -9 | 6 | 6 |
| 30 Jun 23 | 0 | -10 | 6 | 5 |
| 31 Mar 23 | 0 | -10 | 6 | 4 |
| 31 Dec 22 | 0 | -10 | 6 | 4 |
| 30 Sep 22 | 0 | -10 | 6 | 5 |
| 30 Jun 22 | 0 | -9 | 5 | 5 |
| 31 Mar 22 | 0 | -8 | 4 | 4 |
| 31 Dec 21 | 0 | -6 | 3 | 3 |
| 30 Sep 21 | 0 | -5 | 2 | 2 |
| 30 Jun 21 | 0 | -4 | 1 | 2 |
| 31 Mar 21 | 0 | -4 | 1 | 2 |
| 31 Dec 20 | 0 | -4 | 1 | 2 |
Quality Earnings: RNXT is currently unprofitable.
Growing Profit Margin: RNXT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RNXT is unprofitable, and losses have increased over the past 5 years at a rate of 12.9% per year.
Accelerating Growth: Unable to compare RNXT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RNXT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).
Return on Equity
High ROE: RNXT has a negative Return on Equity (-108.91%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/09 22:31 |
| End of Day Share Price | 2026/07/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RenovoRx, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Edward Woo | Ascendiant Capital Markets LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |